Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific corporate action regarding share repurchases executed on May 17, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,427.5 pence per share; lowest price paid was 1,412 pence per share.
- Treasury Holdings (Settled): 530,347,927 shares (9.53% of total issued share capital).
- Treasury Holdings (Including Unsettled): 534,547,927 shares (10.62% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,034,274,336 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,600,000 shares for Treasury. This action increased the percentage of total voting rights held in Treasury from the prior settled position to 10.62% when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (530,347,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,034,274,336 shares in issue) for disclosure threshold assessments.
- Check the settlement status of the 1,600,000 shares purchased on May 17, 2012, to reconcile the difference between settled and total Treasury holdings.